Purpose: To determine the relationship between the achieved refractive change and the change in simulated keratometry (K) after myopic laser situ keratomileusis (LASIK) and compare this relationship between custom and conventional treatments.
Setting: Department of Ophthalmology, University of California, Davis, Sacramento, California, and John A. Moran Eye Center, Salt Lake City, Utah, USA.
Background: Recombinant human erythropoietin (rhEPO) is used for the treatment of anemia of prematurity. However, it has also been found to have properties similar to vascular endothelial growth factor (VEGF), the major angiogenic factor implicated in the pathogenesis of retinopathy of prematurity (ROP). We sought to determine whether rhEPO is an independent risk factor for the development of ROP.
View Article and Find Full Text PDF